|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently the utilization of erlotinib with WBRT or SRS is therefore investigational and may be a reasonable option in erlotinib naïve, EGFR mutated patients with refractory BM.
|
26967582 |
2016 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with brain metastases from ALK-rearranged NSCLC treated with radiotherapy (SRS and/or WBRT) and TKIs have prolonged survival, suggesting that interventions to control intracranial disease are critical.
|
26438117 |
2016 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
This Phase I study assesses the safety, tolerability, and maximal tolerated dose of sorafenib administered with SRS to treat 1-4 brain metastases.
|
28488066 |
2017 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
This exploratory analysis of phase III data supports the practice of omitting WBRT for patients with limited brain metastases undergoing SRS and close surveillance.
|
28961826 |
2017 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although no randomized trials have proven the superiority of SRS over other radiation techniques in older patients with brain metastases or benign brain tumors, data extracted from recent randomized studies and large retrospective series suggest that SRS is an effective approach in such patients associated with survival advantages and toxicity profile similar to those observed in young adults.
|
28629376 |
2017 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, postoperative SRS (3 × 9 Gy) to the resection cavity is an effective treatment modality for melanoma brain metastases associated with better local control as compared with fSRS alone.
|
28260130 |
2017 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of WBRT alone, SRS alone, and their combination in the treatment of one or more brain metastases: Review and meta-analysis.
|
28675121 |
2017 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients with resected brain metastases treated with postoperative SRS or fractionated stereotactic radiation therapy (fSRT) from 2012 to 2016 at a single institution were reviewed.
|
29143275 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
A second course of SRS for locally recurrent brain metastases showed encouraging rates of local control.
|
29621341 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases.
|
30213236 |
2018 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Level 2: Due to neurocognitive toxicity, local therapy (surgery or SRS) without WBRT is recommended for patients with ≤4 brain metastases amenable to local therapy in terms of size and location.
|
30629211 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified a consecutive cohort of patients treated with SRS for brain metastases in our institute.
|
31302392 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Surgery, chemotherapy, and/or radiation (whole-brain radiation therapy and stereotactic radiation surgery [WBRT/SRS]) are a clinically established treatment paradigm for patients with brain metastases.
|
31615863 |
2019 |
|
Metastatic malignant neoplasm to brain
|
0.100 |
Biomarker
|
disease |
BEFREE |
to investigate clinical outcomes in patients with large brain metastases from non-small-cell lung cancer (NSCLC) who received surgical resection and postoperative stereotactic radiosurgery or SRS alone.
|
31097084 |
2019 |